ctDNA Testing After Neoadjuvant Chemotherapy and Radical Cystectomy Predicts Recurrence Risk in Patients with MIBC By Ogkologos - May 21, 2026 89 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the TOMBOLA study Source RELATED ARTICLESMORE FROM AUTHOR Mezigdomide-Carfilzomib-Dexamethasone Prolongs PFS Compared with Carfilzomib-Dexamethasone at First Relapse in Patients with Relapsed Or Refractory Multiple Myeloma FDA Approves Durvalumab in Combination with BCG for High-Risk Non-Muscle Invasive Bladder Cancer Systemic Aging Associated with a Higher Risk of Early-Onset Solid Cancers MOST POPULAR EMA Recommends Extension of Indications for Ibrutinib September 11, 2025 Tucatinib Added to Trastuzumab and Capecitabine Continues to Demonstrate a Significant... January 19, 2022 Remodeled CAR T-Cell Therapy Reduces Side Effects in First Clinical Trial February 20, 2020 FDA Approves Belzutifan for Cancers Associated with Von Hippel-Lindau Disease August 17, 2021 Load more HOT NEWS High Frequency of Germline ATM Variants in CLL NHS ‘understaffed and underequipped’ to tackle cancer, say 3 in 4... FDA Approves Vorasidenib for Grade 2 Astrocytoma or Oligodendroglioma with a... Extra or Missing Chromosomes May Help Cancer Cells Survive Treatment
